The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

Viva Biotech Reports 21.3% Net Profit Growth in 2025 Driven by AI and CDMO Expansion

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

Key Facts

1Viva Biotech's revenue reached RMB 1,729.4 million for the year 2025.

Viva Biotech Holdings (1873.HK) announced its annual financial results for 2025, reporting total revenue of RMB 1,729.4 million. The company's net profit saw a significant year-over-year increase of 21.3%, reaching RMB 269.3 million. Gross profit margin improved by 3.3 percentage points to 37.9%, showcasing enhanced operational efficiency across its business segments. This growth was primarily fueled by the optimization of Langhua Pharmaceutical's business mix and the scaling of CDMO services. Furthermore, the integration of AI-driven drug discovery and improved performance in the CRO sector contributed to the strong financial outcome. These results highlight Viva Biotech's successful transition toward a more technology-intensive and efficient service model in the global biotech market.